Corrigendum: Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus (vol 10, 1151, 2019)

Soria-Juan, B. (Bárbara); Escacena, N. (Natalia); Capilla-González, V. (Vivian); Aguilera, Y. (Yolanda); Llanos, L. (Lucía); Tejedo, J.R. (Juan R.); Bedoya, F.J. (Francisco J.); Juan, V. (Verónica); Martinez-de-la-Cuesta, A. (Antonio); Ruiz-Salmerón, R. (Rafael); Andreu, E.J. (Enrique José); Grochowicz, L. (Lukasz); Prosper-Cardoso, F. (Felipe); Sanchez-Guijo, F.M. (Fermín M.); Lozano, F.S. (Francisco S.); Miralles, M. (Manuel); Río-Solá, L. (Lourdes) del; Castellanos, G. (Gregorio); Moraleda, J. M. (José M.); Sackstein, R. (Robert); García-Arranz, M. (Mariano); Garcia-Olmos, D. (Damián); Martín, F. (Franz); Hmadcha, A. (Abdelkrim); Soria, B. (Bernat)

Palabras clave :

Corrigendum
Cellular medicaments
Cell-based therapy
Clinical trials
Diabetes
Critical limb ischemia
Cost-effectiv

Fecha de publicación :

2020

Editorial :

Frontiers Media

ISSN :

1664-3224

Nota:

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Cita:

Soria-Juan, B. (Bárbara); Escacena, N. (Natalia); Capilla-González, V. (Vivian); et al. "Corrigendum: Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus (vol 10, 1151, 2019)". Frontiers in immunology. 11, 2020, 2029

Resumen

Reference 86 was also included as “Escacena N. Cellular medication as a therapeutic alternative in chronic critical limb ischemia in diabetic patients without the possibility of revascularization. Dissertation Thesis. Sevilla Spain: University of Sevilla. (2016)”. This reference should be included as number 107 “Escacena N. Cellular medication as a therapeutic alternative in chronic critical limb ischemia in diabetic patients without the possibility of revascularization (Dissertation Thesis). University of Sevilla, Seville, Spain (2016).”

URI :

https://hdl.handle.net/10171/67958

DOI:

10.3389/fimmu.2020.02029

Aparece en las colecciones:

DA - CUN - Área de Terapia Celular - Artículos de revista

Ficheros en este ítem: